Latest filing published 22 Jun 2026 for Recursion Pharmaceuticals, INC..
Filing timeline
BuySaleInsider track record
No signal scores available.
Namandje Bumpus: trading record in brief
Namandje Bumpus appears in our data through filings on Recursion Pharmaceuticals, Inc. shares, published by SEC (Form 4). In total, 5 filings cover trades dated from 17 March 2025 to 18 June 2026.
The open-market record consists of 2 sales worth €24k, with no purchase. Outside the open market, there are 3 share grants. In 2026 alone, the filings show no purchases and 2 sales.
Most recently, on 22 June 2026, the filings show an open-market sale worth €11k in Recursion Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Namandje Bumpus
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 88,424 sharesClass A Common StockSEC:0001601830-26-000082:0
- 3,963 sharesClass A Common StockSEC:0001601830-26-000082:1
- 4,386 shares@ US$3.540.0007% mcap35.4% of flowClass A Common StockSEC:0002060594-26-000003:0
- 11,008 shares0Class A Common StockSEC:0001601830-25-000108:0
- 36,549 shares0Class A Common StockSEC:0001601830-25-000048:0
5 of 5 declarations
